Investor Presentaiton

R&D investor presentation 39 AM833 and semaglutide decreases appetite via two complementary mechanisms Semaglutide and AM833 are distributed to specific regions in the hypothalamus and hindbrain Semaglutide Hypothalamus AN 961 people with BMI: 27.0 39.9 kg/m² Phase 1 trial design C6: amylin 4.5 mg OW + sema 2.4 mg OW C5: amylin 2.4 mg OW + sema 2.4 mg OW C4: amylin 1.2 mg OW + sema 2.4 mg OW C3: amylin 0.6 mg OW + sema 2.4 mg Ow C2: amylin 0.3 mg OW + sema 2.4 mg OW Homeostatic signals through hypothalamus AM8331 Hindbrain AP NTS Meal-generated signals through hindbrain AP: area postrema; AN: arcuate nucleus; NTS, nucleus tractus solitarius; OW: once-weekly. ¹AM833 may act in other brain areas, including the hypothalamus, nucleus accumbens and the ventral tegmental area C1: amylin 0.16 mg OW + sema 2.4 mg OW Primary endpoint 20-week treatment Number of treatment emergent adverse events recorded from time of first dosing until follow-up 1 Inclusion criteria: Males or females of non-child-bearing potential, age ≥18-55 yrs. Atherosclerotic cardiovascular disease risk < 5%, double-blinded, placebo controlled, randomised 12:4. BMI: body-mass index; OW: once-weekly. Note: Cohort 6 has yet not finalised. novo nordisk

View entire presentation